Recently, a visit to the accelerator room at New Journey Health Technology Group Co.,Ltd. (Langfang Airport Free Trade Zone) Group Co., Ltd. revealed staff conducting final adjustments on a medical electron linear accelerator. "This integrated CT and accelerator system is specifically engineered for tumor radiotherapy, combining positioning and treatment within a single device," explained Chen Donglei, Director of the Electronics and Electrical Department at the company. "It eliminates the need for repeated patient transfers, streamlining the treatment workflow while significantly enhancing radiotherapy precision." The application of this equipment offers cancer patients a more efficient and accurate new option for radiotherapy.
As a Sino-foreign joint venture medical industry group, New Journey Health focuses on two core sectors: high-end medical equipment manufacturing and chain-based oncology medical services. Adhering to a "resource integration + technology-driven" strategy, the company delves into the forefront of medical industry innovation. It strategically prioritizes seven advanced technological fields: proton and heavy-ion radiotherapy, boron neutron capture therapy, X-ray imaging and diagnostics, nuclear medicine, mechanical engineering, computing and artificial intelligence, and bioengineering with nuclear pharmaceutical applications. This approach aims to build an integrated ecosystem where the technology chain, industrial chain, and value chain converge, providing comprehensive AI-powered precision radiotherapy solutions.
In the medical imaging laboratory, another core technological achievement is drawing significant attention—an optical surface guidance system currently in the debugging phase. Unlike traditional proton therapy gantries, this system innovatively employs a robot-controlled treatment couch rotation design, enabling real-time tracking of patient surface changes to ensure treatment efficacy. "This is an advanced image-guided radiation therapy technology," said Hu Jinsong, Executive Vice President of the Central Research Institute at New Journey Health (Langfang Airport Free Trade Zone) Group Co., Ltd. "It utilizes optical cameras to project invisible structured light. After capturing the reflected signals, it rapidly reconstructs a high-precision 3D point cloud model of the patient's surface. This allows for monitoring patient position changes throughout treatment with sub-millimeter accuracy. If any deviation is detected, the radiotherapy is automatically paused, reinforcing treatment safety."
Compared to traditional radiotherapy systems, the optical surface guidance system represents a revolutionary upgrade from "point" to "surface" monitoring. It not only improves patient comfort and reduces overall treatment time but also serves as a critical enabler for advanced radiotherapy techniques like deep inspiration breath hold and stereotactic body radiotherapy. The experimental setup for this system is now largely complete, with product realization expected in approximately six months.
Innovation and R&D efforts continue unabated, with New Journey Health achieving breakthroughs in multiple proprietary technologies. The company is intensively developing core components for its self-developed superconducting helium ion therapy system. This equipment boasts a positioning accuracy of 0.2 millimeters and is suitable for treating complex tumors in the head, neck, pancreas, and pediatric cases, demonstrating significant clinical application value. A radiotherapy information system built on AI technology has completed its design phase and is about to enter data training. This system will assist doctors in diagnosis and target delineation, empowering intelligent upgrades in diagnosis and treatment. Furthermore, the company's self-developed "Pencil Beam Scanning Treatment Head System" won second prize in the HICOOL 2025 Global Entrepreneurship Competition and has now entered the clinical implementation stage. It will leverage proton and heavy-ion therapy systems to provide precise treatment services for cancer patients.
To seize development opportunities and consolidate industrial advantages, in 2024, New Journey Health relocated its entire R&D and production base, previously located in Shenzhen, to the Airport Economic Zone (Langfang). Leveraging the Beijing-Tianjin-Hebei region's rich industrial resources, ample talent supply, and high-quality innovation ecosystem, the company's growth momentum continues to strengthen. To date, cumulative signed orders have reached 15 billion yuan, reflecting steadily increasing market recognition.
"The Airport Economic Zone (Langfang) provides an excellent innovation ecosystem and industrial support for enterprises," stated Wang Baodong, CEO of New Journey Health (Langfang Airport Free Trade Zone) Group Co., Ltd. "The talent, technological, and resource advantages stemming from the coordinated development of the Beijing-Tianjin-Hebei region have laid a solid foundation for our R&D into domestically produced high-end radiotherapy equipment." He emphasized that the group remains committed to a "clinical orientation," deepening its focus on the two core areas of high-end medical equipment and oncology medical services. The company will continuously strengthen technological innovation and industrial collaboration, deepen university-enterprise industry-academia-research partnerships, accelerate the transformation of cutting-edge technological achievements, overcome "bottleneck" technologies in the field of cancer radiotherapy, and advance tumor diagnosis and treatment towards greater precision, intelligence, and localization. The ultimate goal is to make domestically produced high-end medical equipment benefit more patients.
Comments